Maravai expands again to meet mRNA therapy and vaccine demand

Company expands TriLink BioTechnologies CleanCap capacity and adds new plasmid DNA manufacturing

Register for free to listen to this article
Listen with Speechify
SAN DIEGO—Maravai LifeSciences, a global provider of life-sciences reagents and services to researchers and biotech innovators, is expanding its contract development and manufacturing organization (CDMO) capabilities at TriLink BioTechnologies for the second time in less than a year. The expansion is expected to be completed in the first quarter of 2021 and will increase TriLink’s small-molecule manufacturing capacity with a focus on additional scale-up of CleanCap, its proprietary messenger RNA (mRNA) capping technology, for global mRNA vaccine and therapeutic programs. To further address the increasing demand for mRNA development and clinical programs, the company is currently completing the construction of its plasmid DNA production facility as well.
In November 2019, TriLink opened their new headquarters in San Diego and expanded mRNA and small-molecule capacity as it opened five cGMP-certified suites. The current investment will further expand the operation with an additional three cGMP suites and four cGMP manufacturing support suites.
According to the company, the expansion positions TriLink to meet global demand for research- and GMP-grade CleanCap capping reagent, nucleoside triphosphates and development and cGMP services for mRNA therapeutics and vaccine production. The increase in demand for these critical raw materials and active pharmaceutical ingredients is being driven not only by COVID-19 vaccine development but also by the rapid growth in investigational mRNA therapeutics and advancements in gene editing and cell therapy such as CRISPR, base editors and CAR-T therapies.
“Biotech startups to large biopharma customers are outsourcing production to specialized CDMOs like TriLink to achieve efficiencies and ensure quality. TriLink’s second expansion provides these innovators with a single qualified and complete production partner for their nucleic acid and small molecule research and clinical programs,” said Carl Hull, CEO of Maravai LifeSciences.
Added Brian Neel, chief operating officer of TriLink BioTechnologies: “By integrating plasmid DNA production, TriLink is eliminating the risk of production slowdowns from global supply bottlenecks and streamlining the path to and through clinical trials for our customers. Other measures we’re taking include a move to a 24-hour, seven-day-a-week manufacturing schedule and regular COVID-19 testing of our workforce.”
CleanCap is a co-transcriptional 5’ capping technology that generates what Maravai and TriLink say is a natural Cap 1 structure with higher mRNA capping efficiencies. CleanCap reportedly increases mRNA yields during transcription, simplifies and shortens the mRNA manufacturing process and results in higher levels of protein production. TriLink has developed a suite of CleanCap analogs that are tailor-made for therapeutics and vaccines.

Published In:

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

March 2024 Issue Front Cover

Latest Issue  

• Volume 20 • Issue 2 • March 2024

March 2024

March 2024 Issue